Sucrase Isomaltase Deficiency clinical trials at UCSF
1 research study open to eligible people
Sucrase isomaltase deficiency means you have trouble digesting certain sugars. UCSF is recruiting for a study testing a treatment called Sucraid for symptoms of CSID in people with low, moderate, or normal levels of sucrase. The study uses a 7-day dose of Sucraid.
7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels
open to eligible people ages 6 months to 17 years
This is a Phase 4, U.S. only, multi-center study using a 7-day therapeutic response dose (TRD) of commercial Sucraid® to assess the response of treatment in 1100 symptomatic pediatric (6 months to 17 years old) subjects with low, moderate, and normal sucrase activity determined by a disaccharidase assay via EGD within 1 year of the Screening Visit. This study will also explore the relationship between known genetic CSID mutations and sucrase activities via (EGD) disaccharidase assay (low, moderate, and normal).
Oakland, California and other locations